➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Boehringer Ingelheim
Moodys
Johnson and Johnson
Colorcon

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CETIRIZINE HYDROCHLORIDE HIVES Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cetirizine Hydrochloride Hives patents expire, and when can generic versions of Cetirizine Hydrochloride Hives launch?

Cetirizine Hydrochloride Hives is a drug marketed by Dr Reddys Labs Ltd, Ipca Labs Ltd, Marksans Pharma, Mylan, Orchid Hlthcare, Perrigo R And D, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Unichem, Unique Pharm Labs, Aurobindo Pharma Ltd, Bionpharma Inc, Amneal Pharms Ny, Taro, and Torrent Pharms Llc. and is included in seventeen NDAs.

The generic ingredient in CETIRIZINE HYDROCHLORIDE HIVES is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-three suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Cetirizine Hydrochloride Hives

A generic version of CETIRIZINE HYDROCHLORIDE HIVES was approved as cetirizine hydrochloride by TEVA PHARMS on May 27th, 2008.

  Start Trial

Drug patent expirations by year for CETIRIZINE HYDROCHLORIDE HIVES
Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityPhase 4
Ciusss de L'Est de l'Île de MontréalPhase 3
TerSera TherapeuticsPhase 2

See all CETIRIZINE HYDROCHLORIDE HIVES clinical trials

Pharmacology for CETIRIZINE HYDROCHLORIDE HIVES

US Patents and Regulatory Information for CETIRIZINE HYDROCHLORIDE HIVES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Torrent Pharms Llc CETIRIZINE HYDROCHLORIDE HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 079191-003 Apr 15, 2010 OTC No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd CETIRIZINE HYDROCHLORIDE HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 090760-002 Aug 5, 2015 OTC No No   Start Trial   Start Trial   Start Trial
Torrent Pharms Llc CETIRIZINE HYDROCHLORIDE HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 079191-002 Apr 15, 2010 OTC No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd CETIRIZINE HYDROCHLORIDE HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 090760-004 Aug 5, 2015 OTC No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
McKinsey
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.